The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs

Garcia-Carbonero, R.Benavent, M.Fonseca, P. JimenezCastellano, D.Alonso-Gordoa, T.Teule, A.Custodio, A.Tafuto, S.La Casta, A.Spada, F.Lopez, C.Ibrahim, T.Silva, M. J. VillanuevaIranzo, V.Garcia-Alfonso, P.Gonzalez-Flores, E.Grande, E.Crespo, G.Carmona-Bayonas, A.Capdevila, J.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/26495enThe AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETsconference outputopen access10.1016/j.annonc.2021.08.1791569-8041https://doi.org/10.1016/j.annonc.2021.08.179700527702115